How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?
Jimin Han, Director of Sustainability, Samsung Biologics
Devising actionable plans for reducing a product's carbon footprint and maintaining reliable manufacturing supply chains are two of the most decisive factors that define a pharma/biopharma's ESG commitment.
Decarbonizing the entire cycle of drug manufacturing from scope 1 to 3 emissions requires a long-term collaboration among drug makers, contract development and manufacturing organizations (CDMOs), and raw material suppliers. The role of CDMOs in facilitating this collaboration is critical.
Jimin Han, Director of Sustainability, Samsung Biologics
Devising actionable plans for reducing a product's carbon footprint and maintaining reliable manufacturing supply chains are two of the most decisive factors that define a pharma/biopharma's ESG commitment.
Decarbonizing the entire cycle of drug manufacturing from scope 1 to 3 emissions requires a long-term collaboration among drug makers, contract development and manufacturing organizations (CDMOs), and raw material suppliers. The role of CDMOs in facilitating this collaboration is critical.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article